A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate
- 1 December 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature
- Vol. 590 (7845), 320-325
- https://doi.org/10.1038/s41586-020-3035-9
Abstract
The explosively expanding COVID-19 pandemic urges the development of safe, efficacious and fast-acting vaccines. Several vaccine platforms are leveraged for a rapid emergency response1. We describe the discovery of a live virus-vectored SARS-CoV-2 vaccine candidate using the yellow fever 17D (YF17D) vaccine as vector to express a non-cleavable prefusion form of the SARS-CoV-2 Spike antigen. We assess vaccine safety, immunogenicity and efficacy in several animal models. Vaccine candidate YF-S0 has an outstanding safety profile and induces high levels of SARS-CoV-2 neutralizing antibodies in hamsters, mice and cynomolgus macaques and concomitantly a protective immunity against YFV. Humoral immunity is complemented by a favourable Th1 cell-mediated immune response as profiled in mice. In a stringent hamster model2 as well as in non-human primates, YF-S0 prevents infection with SARS-CoV-2. Moreover, in hamsters, a single dose confers protection from lung disease in most vaccinated animals within 10 days. Taken together, the quality of immune responses triggered and the rapid kinetics by which protective immunity can be mounted already after a single dose warrant further development this potent SARS-CoV-2 vaccine candidate.This publication has 77 references indexed in Scilit:
- Simple and inexpensive three-step rapid amplification of cDNA 5′ ends using 5′ phosphorylated primersAnalytical Biochemistry, 2013
- Induction of Alternatively Activated Macrophages Enhances Pathogenesis during Severe Acute Respiratory Syndrome Coronavirus InfectionJournal of Virology, 2012
- The Safety of Yellow Fever Vaccine 17D or 17DD in Children, Pregnant Women, HIV+ Individuals, and Older Persons: Systematic ReviewThe American Journal of Tropical Medicine and Hygiene, 2012
- A Vesicular Stomatitis Virus Replicon-Based Bioassay for the Rapid and Sensitive Determination of Multi-Species Type I InterferonPLOS ONE, 2011
- Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccinesJournal of Virological Methods, 2010
- Viruses as vaccine vectors for infectious diseases and cancerNature Reviews Microbiology, 2009
- A Mouse Model for Studying Viscerotropic Disease Caused by Yellow Fever Virus InfectionPLoS Pathogens, 2009
- The spike protein of SARS-CoV — a target for vaccine and therapeutic developmentNature Reviews Microbiology, 2009
- Construction and characterization of recombinant flaviviruses bearing insertions between E and NS1 genesVirology Journal, 2007
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001